MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$57,575K
EPS
-$0.53
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
47,548
42,651
44,831*
37,480
General and administrative
14,395
11,464
12,372*
9,378
Total operating expenses
61,943
54,115
57,203
46,858
Loss from operations
-61,943
-54,115
-57,203*
-46,858
Interest income
4,616
5,102
4,581
6,192
Total other income
4,616
5,102
4,581*
6,192
Net loss
-57,327
-49,013
-52,623*
-40,666
Unrealized gain on available-for-sale securities, net
-248
-929
-193*
497
Total comprehensive loss
-57,575
-49,942
-52,816
-40,169
Basic EPS
-0.53
-0.46
-0.537
-0.39
Diluted EPS
-0.53
-0.46
-0.537
-0.39
Basic Average Shares
107,669,774
107,116,709
98,358,960
105,492,779
Diluted Average Shares
107,669,774
107,116,709
98,358,960
105,492,779
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$57,575K
(-58.56%↓ Y/Y)
Interest income
$4,616K
(-28.93%↓ Y/Y)
Net loss
-$57,327K
(-58.73%↓ Y/Y)
Unrealized gain on
available-for-sale securities, net
-$248K
(-25.89%↓ Y/Y)
Total other income
$4,616K
(-28.93%↓ Y/Y)
Loss from operations
-$61,943K
(-45.37%↓ Y/Y)
Total operating
expenses
$61,943K
(45.37%↑ Y/Y)
Research and development
$47,548K
(41.69%↑ Y/Y)
General and
administrative
$14,395K
(59.03%↑ Y/Y)
Buy us a coffee
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)